Let me try it very quickly at a high level, and then Dr. Sanders can pick up from there.
With respect to the clinical effectiveness, there are about 400 oncology drugs in the pipeline right at the moment, and each one of these has an approximate cost for treatment of about $50,000 per patient. You work out the numbers, and in a little province like Saskatchewan, if you approved all of these clinically, it'd be about $600 million a year incremental cost. We have to consider not just the clinical effectiveness but also the cost-effectiveness on this.
With respect to the go-forward game plan, there really is a great plan out there. The foundation currently is the CDR. It is CADTH, it is the CDR. Again, when I was here last time, we talked about the national pharmaceutical strategy. Saskatchewan is working on the common formulary. B.C. is working on expensive drugs for rare diseases. Alberta and Manitoba are working very closely on a catastrophe program. We've set up a new oncology review process, piggybacking off the Ontario system as a pilot for many of the provinces, given drugs that have come on, which have been very expensive, and we're not certain about their cost-effectiveness.
So the game plan at the end of the day would be, from the perspective of many provinces, let's have a national pharmaceutical system, number one. Number two, let's have the common drug review and let's incorporate oncology drugs into that review.